[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 923,790
  • Shares Outstanding, K 641,521
  • Annual Sales, $ 183,880 K
  • Annual Income, $ -83,500 K
  • EBIT $ -35 M
  • EBITDA $ -39 M
  • 60-Month Beta 0.60
  • Price/Sales 5.02
  • Price/Cash Flow N/A
  • Price/Book 4.03

Options Overview Details

View History
  • Implied Volatility 117.66% (+29.02%)
  • Historical Volatility 48.11%
  • IV Percentile 47%
  • IV Rank 12.53%
  • IV High 429.98% on 10/10/25
  • IV Low 72.92% on 03/20/26
  • Expected Move (DTE 30) 0.2975 (21.10%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 263
  • Volume Avg (30-Day) 602
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 58,630
  • Open Int (30-Day) 56,516
  • Expected Range 1.1125 to 1.7075

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 3
  • High Estimate $0.00
  • Low Estimate $-0.01
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2600 +11.90%
on 07/01/26
1.6200 -12.96%
on 07/09/26
+0.0700 (+5.22%)
since 06/22/26
3-Month
1.0800 +30.56%
on 06/11/26
1.7250 -18.26%
on 05/06/26
-0.1400 (-9.03%)
since 04/22/26
52-Week
1.0400 +35.58%
on 11/07/25
2.0100 -29.85%
on 02/19/26
+0.1300 (+10.16%)
since 07/22/25

Most Recent Stories

More News
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options...

GERN : 1.4100 (-2.08%)
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.4100 (-2.08%)
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a...

GERN : 1.4100 (-2.08%)
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.4100 (-2.08%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options...

GERN : 1.4100 (-2.08%)
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.4100 (-2.08%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.1850 (+21.71%)
BIOA : 21.94 (-3.13%)
LCTX : 1.1100 (-2.63%)
GERN : 1.4100 (-2.08%)
FATE : 2.58 (-8.83%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options...

GERN : 1.4100 (-2.08%)
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population  Additional presentations...

GERN : 1.4100 (-2.08%)
Geron: Q1 Earnings Snapshot

Geron: Q1 Earnings Snapshot

GERN : 1.4100 (-2.08%)

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.4900
2nd Resistance Point 1.4700
1st Resistance Point 1.4400
Last Price 1.4100
1st Support Level 1.3900
2nd Support Level 1.3700
3rd Support Level 1.3400

See More

52-Week High 2.0100
Fibonacci 61.8% 1.6395
Fibonacci 50% 1.5250
Fibonacci 38.2% 1.4105
Last Price 1.4100
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.